Morphine Sulfate
Total Payments
$183,420
Transactions
15
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $168,801 | 3 | 0 |
| 2023 | $8,410 | 5 | 0 |
| 2022 | $3,141 | 3 | 0 |
| 2021 | $1,000 | 1 | 0 |
| 2019 | $1,906 | 1 | 0 |
| 2017 | $161.24 | 2 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $180,117 | 10 | 98.2% |
| Consulting Fee | $3,141 | 3 | 1.7% |
| Food and Beverage | $161.24 | 2 | 0.1% |
Payments by Type
Research
$180,117
10 transactions
General
$3,303
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Opioid / BTOD REMS | Hikma Pharmaceuticals USA | $177,211 | 0 |
| Morphine Pediatric Study | Hikma Pharmaceuticals USA | $1,906 | 0 |
| Opioid PMR Study | Hikma Pharmaceuticals USA | $1,000 | 0 |
Ad
Manufacturing Companies
- Hikma Pharmaceuticals USA $183,259
- Fresenius Kabi USA, LLC $161.24
Product Information
- Type Drug
- Total Payments $183,420
- Total Doctors 2
- Transactions 15
About Morphine Sulfate
Morphine Sulfate is a drug associated with $183,420 in payments to 2 healthcare providers, recorded across 15 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2017 to 2024. In 2024, $168,801 was paid across 3 transactions to 0 doctors.
The most common payment nature for Morphine Sulfate is "Unspecified" ($180,117, 98.2% of total).
Morphine Sulfate is associated with 3 research studies, including "Opioid / BTOD REMS" ($177,211).